European Neuropsychopharmacology
Volume 20, Issue 10 , Pages 683-687 , October 2010

Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa

  • A. Antonini

      Affiliations

    • Ist. Clinici Perfezionamento, Parkinson Institute, Milan, Italy
    • IRCCS San Camillo, Venezia, Italy
    • ,
  • G. Bondiolotti

      Affiliations

    • Dept. of Pharmacology, University of Milan, Milan, Italy
    • ,
  • F. Natuzzi

      Affiliations

    • Ist. Clinici Perfezionamento, Parkinson Institute, Milan, Italy
    • ,
  • S.R. Bareggi

      Affiliations

    • Dept. of Pharmacology, University of Milan, Milan, Italy
    • Corresponding Author InformationCorresponding author. Dept. of Pharmacology, University of Milan, Via Vanvitelli 32, 20129 Milano, Italy. Tel.: +39 02 5031 6946.

Received 9 February 2010 ,Revised 26 April 2010 ,Accepted 30 April 2010.

References 

  1. Antonini A, Isaias IU, Canesi M, Zibetti M, Mancini F, Manfredi L, et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov. Disord. 2007;22:1145–1149
  2. Bet L, Bareggi SR, Pacei F, Bondiolotti G, Meola G, Schapira AH. Bimodal administration of entacapone in Parkinson's disease patients improves motor control. Eur. J. Neurol. 2008;15:268–273
  3. Clarke CE, Zobkiw RM, Gullaksen E. Quality of life and care in Parkinson's disease. Br. J. Clin. Pract. 1995;49:288–293
  4. Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part 1. Ann. Neurol. 1988;24:366–371
  5. Fahn S, Elton RL, the UPDRS Development Committee . Unified Parkison's disease rating scale. In:  Fahn S,  Mardsen CD,  Goldstein M,  Calne D editor. Recent Developments in Parkinson's Disease. Florham Park, NJ: MacMillan Healthcare Information; 1987;p. 153–163
  6. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch. Neurol. 2004;61:1044–1053
  7. Karlsen KH, Tandberg E, Arsland D, Larsen JP. Health related quality of life in Parkinson's disease: a prospective longitudinal study. J. Neurol. Neurosurg. Psychiatry. 2000;69:584–589
  8. Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology. 1991;41:202–205
  9. Kurth MC, Tetrud JW, Tanner CM, Irwin I, Stebbins GT, Goetz CG, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with ‘on-off’ fluctuations. Neurology. 1993;43:1698–1703
  10. Müller T, Kuhn W. Tolcapone decrease plasma levels of S-adenosyl-l-homocysteine and homocystiene in treated Parkinson's disease patients. Eur. J. Clin. Pharmacol. 2006;62:447–450
  11. Müller T, Woitalla D, Hauptmann B, Fowler B, Kuhn W. Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease. Neurosci. Lett. 2001;308:54–56
  12. Nyholm D, Nilsson Remahl AI, Dizdar N, et al.  Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology. 2005;64:216–223
  13. Olanow W, Schapira AH, Rascol O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci. 2000;23(10 suppl):S117–S126
  14. Parkinson Study Group . Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann. Neurol. 1997;42(5):747–755
  15. Piccini P, Brooks DJ, Korpela K, Pavese N, Karlsson M, Gordin A. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 2000;68:589–594
  16. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J. Med. 2000;342:1484–1491
  17. Shapira AH. Treatment options in the modern management of Parkinson disease. Arch. Neurol. 2007;64:1083–1088
  18. Shoulson I, Glaubiger GA, Chase TN. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology. 1975;25(12):1144–1148
  19. Stocchi F, Vacca L, Ruggieri S, Olanow W. Intermittent versus continuous levodopa administration in patients with advanced Parkinson's disease. Arch. Neurol. 2005;62:905–910
  20. Wikberg T. Simultaneous determination of levodopa, its main metabolites and carbidopa in plasma by liquid chromatography. J. Pharm. Biomed. Anal. 1991;9:167–176

PII: S0924-977X(10)00092-1

doi: 10.1016/j.euroneuro.2010.04.010

European Neuropsychopharmacology
Volume 20, Issue 10 , Pages 683-687 , October 2010

Article Tools

* Image Usage & Resolution